What is the 13F Pro Quality Score for ICCC?

13F Pro ranks IMMUCELL CORP /DE/ (ICCC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ICCC's current score at https://13fpro.ai/company/ICCC (free sign-up required for the full ranking).

Where does 13F Pro source ICCC data?

All IMMUCELL CORP /DE/ fundamentals and ownership data come directly from SEC EDGAR. IMMUCELL CORP /DE/ files with the SEC under CIK 811641. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ICCC in?

IMMUCELL CORP /DE/ (ICCC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ICCC research updated on 13F Pro?

ICCC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IMMUCELL CORP /DE/(ICCC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 811641 ICCC stock profile & AI dashboard →

13F Pro Quality Score

51.3/100

Rank #1,548 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

78.7/100

Profitability

32.5/100

Balance Sheet

51.0/100

Earnings Quality

97.4/100

Free Cash Flow

63.2/100

Institutional Flow

23.1/100

Revenue Scale

5.3/100

Dilution Risk

54.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ICCC Scores 51/100

exact factor attribution · 2026-09-11

ICCC's composite is driven by revenue growth and earnings quality, held back by scale and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+5.7 pts

79th pct

Earnings quality

+4.7 pts

97th pct

Free cash flow

+2.0 pts

63th pct

Shareholder dilution

+0.2 pts

54th pct

Capital efficiency

+0.1 pts

51th pct

Earnings growth

-0.8 pts

34th pct

Institutional flow

-1.3 pts

23th pct

Profitability

-2.6 pts

33th pct

Scale

-6.7 pts

5th pct

Latest change (2026-08-13): 65 → 57 · ↓ Revenue growth 85→59; ↓ Free cash flow 71→53

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ICCC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for IMMUCELL CORP /DE/ (ICCC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ICCC at 51.3/100 on a 32-signal composite quality model, placing it at rank #1,548 of 2,962 stocks — the bottom half of the AI-ranked universe. ICCC scores in the top quartile across earnings quality (97.4), revenue growth (78.7). Areas of concern include revenue scale (5.3) and institutional flow (23.1), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), IMMUCELL CORP /DE/ reports quarterly revenue of $7.2M, net income of $1.8M, free cash flow of $2.3M. Top institutional holders of ICCC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. ICCC trades on the Nasdaq exchange and files with the SEC under CIK 811641. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICCC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IMMUCELL CORP /DE/ directly from SEC EDGAR. IMMUCELL CORP /DE/'s 13F Pro composite quality score has ranged between 19 and 57 since 2025, currently 51.3 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about IMMUCELL CORP /DE/

Quirks, history, and lore behind ICCC — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. animal health company · listed on Nasdaq · headquartered in Maine.
2
The Numbers
Annual revenue in the range of tens of millions of dollars — this is decidedly micro-cap territory, serving a niche market most investors have never thought about.
3
The History
Founded in the 1980s, the company carved out a narrow lane in veterinary biologics and pharmaceuticals, focusing almost entirely on dairy and beef cattle.
4
The Secret
Its core mission is fighting mastitis — a costly bacterial udder infection — which costs the dairy industry billions of dollars annually worldwide.
5
The Lore
Its flagship product is one of the very few FDA-approved treatments specifically targeting staph aureus mastitis in dairy cows — a remarkably specific moat for a tiny company.
6
The Giveaway
Ticker ICCC, based in Portland, Maine — this little biotech's whole identity is keeping dairy cows healthy, one udder at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$7.2M

Net Income

Q2 2026

$1.8M

Free Cash Flow

Q2 2026

$2.3M

ROIC

Q2 2026

18.8%

D/E Ratio

Q2 2026

0.31

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.3% YoY

$27.6MFY 2025

FY22 $18.6MFY23 $17.5MFY24 $26.5MFY25 $27.6M

Net Income

+51.8% YoY

$-1.0MFY 2025

FY22 $-2.5MFY23 $-5.8MFY24 $-2.2MFY25 $-1.0M

Operating Income

+200.6% YoY

$1.6MFY 2025

FY22 $-2.3MFY23 $-5.7MFY24 $-1.6MFY25 $1.6M

EPS (Diluted)

+53.8% YoY

$-0.12FY 2025

FY22 $-0.32FY23 $-0.75FY24 $-0.26FY25 $-0.12

Total Assets

-5.7% YoY

$42.5MFY 2025

FY22 $44.9MFY23 $43.8MFY24 $45.1MFY25 $42.5M

Total Debt

-11.0% YoY

$10.7MFY 2025

FY22 $20.2MFY23 $22.4MFY24 $12.0MFY25 $10.7M

Op. Cash Flow

+591.6% YoY

$2.5MFY 2025

FY22 $-1.5MFY23 $-4.7MFY24 $357.9KFY25 $2.5M

Free Cash Flow

+1236.0% YoY

$1.2MFY 2025

FY22 $-5.5MFY23 $-6.6MFY24 $-107.8KFY25 $1.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$27.6M +4.3%	$26.5M +51.6%	$17.5M -5.9%	$18.6M -3.5%	$19.2M +25.4%	$15.3M
Net Income	$-1.0M +51.8%	$-2.2M +62.7%	$-5.8M -131.6%	$-2.5M -3085.3%	$-78.3K +92.3%	$-1.0M
Operating Income	$1.6M +200.6%	$-1.6M +71.5%	$-5.7M -150.0%	$-2.3M -993.2%	$257.4K +118.6%	$-1.4M
EPS (Diluted)	$-0.12 +53.8%	$-0.26 +65.3%	$-0.75 -134.4%	$-0.32 -3100.0%	$-0.01 +92.9%	$-0.14
Total Assets	$42.5M -5.7%	$45.1M +3.0%	$43.8M -2.3%	$44.9M +0.9%	$44.5M +10.2%	$40.3M
Total Debt	$10.7M -11.0%	$12.0M -46.3%	$22.4M +11.1%	$20.2M +2383.0%	$812.2K -91.4%	$9.5M
Operating Cash Flow	$2.5M +591.6%	$357.9K +107.7%	$-4.7M -202.8%	$-1.5M -261.8%	$954.2K -27.5%	$1.3M
Free Cash Flow	$1.2M +1236.0%	$-107.8K +98.4%	$-6.6M -19.0%	$-5.5M -233.6%	$-1.7M +40.0%	$-2.8M

Get alerted when ICCC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IMMUCELL CORP /DE/ including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ICCC

VANGUARD CAPITAL MANAGEMENT LLC
$2.7M268,130 sh
MORGAN STANLEY
$2.4M233,910 sh
RENAISSANCE TECHNOLOGIES LLC
$1.7M171,089 sh
Cresset Asset Management, LLC
$1.4M135,267 sh
GEODE CAPITAL MANAGEMENT, LLC
$726.5K72,270 sh
DIMENSIONAL FUND ADVISORS LP
$587.4K58,452 sh
Bleichroeder LP
$502.5K50,000 sh
Steadtrust LLC
$456.0K45,370 sh
Mesirow Financial Investment Management, Inc.
$426.9K42,481 sh
CITADEL ADVISORS LLC
$407.1K40,503 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$2.7M	268,130
MORGAN STANLEY	$2.4M	233,910
RENAISSANCE TECHNOLOGIES LLC	$1.7M	171,089
Cresset Asset Management, LLC	$1.4M	135,267
GEODE CAPITAL MANAGEMENT, LLC	$726.5K	72,270
DIMENSIONAL FUND ADVISORS LP	$587.4K	58,452
Bleichroeder LP	$502.5K	50,000
Steadtrust LLC	$456.0K	45,370
Mesirow Financial Investment Management, Inc.	$426.9K	42,481
CITADEL ADVISORS LLC	$407.1K	40,503

Companies Similar to ICCC

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CPIX

CUMBERLAND PHARMACEUTICALS INC

AI score

Similar quality profile · 1 shared holders

BAILARD, INC.

AMS

AMERICAN SHARED HOSPITAL SERVICES

AI score

Similar quality profile

CSBR

CHAMPIONS ONCOLOGY, INC.

AI score

Similar quality profile · 1 shared holders

Mesirow Financial Investment Management, Inc.

APT

ALPHA PRO TECH LTD

AI score

Similar quality profile

KRMD

KORU Medical Systems, Inc.

AI score

Similar quality profile · 1 shared holders

Mesirow Financial Investment Management, Inc.

MMED

MiniMed Group, Inc.

AI score

Similar quality profile · 1 shared holders

Mesirow Financial Investment Management, Inc.

VMD

VIEMED HEALTHCARE, INC.

AI score

Similar quality profile · 1 shared holders

BAILARD, INC.

PBYI

PUMA BIOTECHNOLOGY, INC.

AI score

Similar quality profile · 1 shared holders

BAILARD, INC.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ICCC on your watchlist

Track score changes the day IMMUCELL CORP /DE/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ICCC a good stock to buy?

13F Pro's AI-powered analysis of IMMUCELL CORP /DE/ (ICCC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ICCC are available on the ICCC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ICCC is classified as a small company.

Which hedge funds own ICCC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ICCC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IMMUCELL CORP /DE/'s investment landscape.